Article
Adenosine kinase is a key determinant for the anti-HCV activity of ribavirin.
Hepatology (Baltimore, Md.) - 1 Oct 2013
Mori Kyoko, Hiraoka Osamu, Ikeda Masanori, Ariumi Yasuo, Hiramoto Akiko, Wataya Yusuke, Kato Nobuyuki
Abstract excerpt
UNLABELLED: Ribavirin (RBV) is often used in conjunction with interferon-based therapy for patients with chronic hepatitis C. There is a drastic difference in the anti-hepatitis C virus (HCV) activity of RBV between the HuH-7-derived assay system, OR6, possessing the RBV-resistant phenotype (50% effective concentration [EC50 ]: >100 µM) and the recently discovered Li23-derived assay system, ORL8, possessing the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
